Funding for this research was provided by:
Received: 1 November 2019
Accepted: 19 May 2020
First Online: 12 June 2020
Ethics approval and consent to participate
: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice and all applicable country-specific requirements and was approved by relevant national, regional, or independent ethics committee or institutional review board. Written informed consent was obtained from each patient prior to the performance of any study procedures.
: Not applicable.
: The authors met the criteria for authorship as recommended by the International Committee of Medical Journal Editors. ZB, RvM, KR and AF are employees of GSK and own stock in GSK. SP, RD and LL were employees of GSK at the time of study and own stocks in GSK. EK is an employee of Crisor LLC Research and has served on advisory boards, speaker panels or received travel reimbursement from Amphastar, AstraZeneca, Boehringer Ingelheim, Forest, GSK, Mylan, Novartis, Pearl, Sunovion, Teva and Theravance. EK has conducted multicentre clinical research trials for approximately 40 pharmaceutical companies. RN was an employee of Asthma & Allergy Associates at the time of the study, and receives grant funding or research support from Aimmune, AstraZeneca, Attenua, Biocryst, Chiesi, Dyax, Genentech, GSK, Lupin, Menlo, Novartis, Pearl, Pfizer, Sanofi Aventis, Shire, Spirosure, Teva, 3M and Watson. RN is also a consultant or scientific advisor for Boehringer Ingelheim, GSK, Optinose, Stallergenes Greer and CSL Behring and receives speaker’s fees from Boehringer Ingelheim, CSL Behring, GSK, Stallergenes Greer and Merck. DB is an employee of the University of Cincinnati College of Medicine and Bernstein Clinical Research Center. DB receives grant/research/clinical trial support from GSK, Teva, AstraZeneca, Pearl, Novartis, Genentech, Lupin, Merck, Mylan, Boehringer Ingelheim, Amgen, Aimmune, Menlo, Shire, Biocryst and provides consultancy or contributes towards advisory boards for GSK, ALK America, Gerson-Lehman and Guidepoint Global. No authors were paid for the development of the manuscript. ELLIPTA is owned by or licensed to the GSK group of companies.